Modified live (JMSO strain) Haemophilus parasuis vaccine
AssigneeNewport Laboratories, Inc.
InventorsKamesh R. Sirigireddy, Paulraj K. Lawrence, Russell F. Bey, Randy R. Simonson
Life of this patent
Estimating the term…
Abstract
The present invention is a live vaccine from a culture of cells of Haemophilus parasuis exhibiting attenuated pathogenicity and capable of triggering a protective immune response when administered to pigs. The cell culture was modified from a pathogenic parent strain by MNNG mutagenesis and was selected by complete dependence on streptomycin for growth. Several SNPs have been identified as associated with specific proteins that are associated with virulence as seen in the literature in H. parasuis or related bacterial species.
Claims22
A vaccine for protecting pigs against infection by H. parasuis, comprising a veterinarily acceptable carrier and an immunologically effective amount of live cells of an isolated strain of a serovar derived from a pathogenic parent strain of H. parasuis, wherein said cells exhibit attenuated pathogenicity in pigs as compared to those of the parent strain and wherein said cells are capable of triggering an immune response that protects the pig against H. parasuis infection or reduction in disease when administered as a live vaccine, wherein the parent strain and the isolated strain are serovar 5 of H. parasuis, wherein the vaccine provides heterologous protection against at least serovars 4 and 13;
- and
- wherein the live cells differ from the virulent parent strain in that they have mutated versions of the genes encoding the 30S ribosomal protein S12, the N-acetyl-D-glucosamine kinase, and the F0F1 ATP synthase subunit C, with respect to the corresponding genes present in the parent strain.
Dependencies are inferred from the claim text.